Aptar Digital Health (ADH) has teamed up with Guy’s and St Thomas’ NHS Foundation Trust in London, UK, to study the impact of its ADH Respiratory DMP platform on asthma patients.
Both organisations have collaborated with Lindus Health, a clinical research organisation (CRO) to execute the study, which began in July this year.
The 12-month clinical study will recruit 118 adults with moderate to severe asthma, to evaluate the improvement of asthma symptoms control with the digital solution.
In addition to the asthma symptoms control, the study will evaluate clinical data including quality of life, asthma controller adherence, healthcare resources and overall satisfaction.
Guy’s and St Thomas’ NHS Foundation Trust asthma and eosinophilic lung diseases consultant and the clinical study chief investigator David Jackson said: “Poor adherence to inhaled steroids remains the biggest barrier to asthma control.
“At the same time, a failure to identify and correct suboptimal adherence leads to unnecessary escalation to very costly biologic agents due to the incorrect assumption many patients have severe asthma when they do not.
“As such, electronic monitoring of ICS adherence has enormous potential to both improve quality of care and reduce healthcare costs in asthma, and we are excited to start this study with the aim of demonstrating this.”
ADH is a digital health company offering Software-as-medical device (SaMD) solutions, digital Patient Support Programs, connected devices, and disease management platforms.
The company said its ADH Respiratory DMP platform is designed to improve asthma symptom control, technique, and engagement.
The platform comprises a patient mobile application that connects to inhaler sensors, including ADH’s HeroTracker Sense, and a software portal for healthcare professionals.
It provides individuals with medication and symptom management with real-time tracking, reminders, and educational resources via a mobile app.
ADH Respiratory DMP platform advances behaviour changes and adherence to reduce asthma symptoms, medication usage, exacerbations, and unnecessary healthcare visits, said ADH.
Aptar Digital Health chief medical officer Geneviève d’Orsay said: “Asthma affects 334 million people worldwide, with between a third and one-half of asthma sufferers having severe symptoms that regularly interfere with everyday life.
“Our respiratory platform previously demonstrated potential to improve asthma control and decrease rescue medication use in the US, and we are excited to study our enhanced platform as part of this clinical study.”
Earlier this year, ADH partnered with SHL Medical, allowing the latter to use its SaMD platform to create digital solutions that help patients manage injectable therapies.
